Skip to main content

Table 3 Dose-volume constraints

From: Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial

Organ at risk

Dose restriction

Bladder

V40 < 50 %

 

V45 < 30 %

Small intestine

No more than 180 cc above 35 Gy

 

No more than 100 cc above 40 Gy

 

No more than 65 cc above 45 Gy

Femoral head

V25 < 45 %

 

V40 < 40 %

 

V50 < 10 %

Back to article page

Trials

ISSN: 1745-6215